Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;209(3):233-235.
doi: 10.1164/rccm.202311-2103ED.

Do Comorbidities Influence the Response to Biologics in Severe Asthma?

Corrado Pelaia  1 , Girolamo Pelaia  2 , William Busse  3
Affiliations
Editorial

Do Comorbidities Influence the Response to Biologics in Severe Asthma?

Corrado Pelaia et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Impact of T2-related comorbidities on the effectiveness of biologics in severe asthma treatment. AR and eczema/AD did not influence the effectiveness of biologics used to treat severe asthma. Chronic rhinosinusitis (CRS) with or without nasal polyps (NP), as well as NP without CRS, further improved biologic effectiveness with regard to reduction of asthma exacerbations and improvement of asthma symptom control. The coexistence of CRS ± NP with severe asthma also led to a significant increase of percent predicted FEV1 (ppFEV1). NP induced a nonsignificant trend (dashed arrow) toward ppFEV1 increase. The LTOCS was not affected by either CRS ± NP or NP. AR = allergic rhinitis; AD = atopic dermatitis; LTOCS = long-term oral corticosteroid daily dose.
See this image and copyright information in PMC

Comment on

  • Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma.
    Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, Murray RB, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, García U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, Perez de Llano L, Perng DS, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Goddard AG, Wang E, Hoyte FCL, Chapman NM, Katial R, Carter V, Bulathsinhala L, Eleangovan N, Ariti C, Lyu J, Porsbjerg C, Price DB. Wechsler ME, et al. Am J Respir Crit Care Med. 2024 Feb 1;209(3):262-272. doi: 10.1164/rccm.202305-0808OC. Am J Respir Crit Care Med. 2024. PMID: 38016003

References

    1. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet . 2023;401:858–873. - PubMed
    1. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45–53. - PMC - PubMed
    1. Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe PJ, Ruddy M, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J . 2021;58:2003393. - PMC - PubMed
    1. Bakakos A, Schleich F, Bakakos P. Biological therapy of severe asthma and nasal polyps. J Pers Med . 2022;12:976. - PMC - PubMed
    1. Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, et al. Association between T2-related comorbidities and effectiveness of biologics in severe asthma. Am J Respir Crit Care Med . 2024;209:262–272. - PubMed

Substances